ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis’ positive impact […]
Financial
Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]
AngioSoma Acquires Technology Related to 15 Patents
Houston, Jan. 15, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that we have acquired the unconditional ownership of the following intellectual property and the exclusive right to develop, formulate and market: · Method and Composition for Reducing Dysfunction in Angioplasty […]
Cardax, Inc. Announces Reverse Stock Split of Common Stock
HONOLULU, Jan. 14, 2020 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) today announced it will effect a 200-for-1 reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Amendment to the Company’s Certificate of Incorporation filed with the Secretary of State of Delaware, the reverse stock split will be effective at 12:01 […]
Zebra Medical Vision Expands Its Footprint in North America and Appoints a New CEO
KIBBUTZ SHEFAYIM, Israel–(BUSINESS WIRE)–Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today that Ohad Arazi has been appointed as Chief Executive Officer, succeeding Co-Founder Eyal Gura, who will continue as Chairman of the board. Mr Arazi brings to Zebra-Med extensive leadership experience in healthcare IT and medical imaging, […]
Matinas BioPharma Announces Closing of Public Offering of Common Stock
BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) — (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of […]
Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019
MARLBOROUGH, Mass., Jan. 14, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company’s guidance range of 13 to 15 percent; approximately 14.1 percent on […]
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2019 and provided 2020 financial guidance. Preliminary, unaudited revenue for fourth quarter 2019 is expected to be approximately […]
Itamar™ Medical Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 and Revenue Guidance for Full Year 2020
– 2019 Fiscal Year Revenues Expected to Increase 29% to $31.1 Million to $31.3 Million – – Full Year 2020 Revenue Guidance of $39.5 Million to $42.0 Million – CAESAREA, Israel, Jan. 13, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a company that develops, manufactures and markets non-invasive […]
Neovasc Inc. Investor Update
VANCOUVER, Jan. 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide an update for investors, including […]



